ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,346.99
-0.11%
US Tech 100
18,488.00
-0.25%
다우존스 지수
38,798.99
-0.22%
Bitcoin
69,466.52
0.19%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Alzamend Neuro Inc (ALZN)

  7. Alzamend Neuro Inc (ALZN) 뉴스

ALZN

Alzamend Neuro (ALZN)

Alzamend Neuro Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ALZN
일자시간출처헤드라인심볼기업
2024/06/0405:30Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ALZNAlzamend Neuro Inc
2024/06/0105:59Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
2024/05/2305:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
2024/05/2221:00Business WireAlzamend Neuro Announces Favorable Decision from Nasdaq Hearings PanelNASDAQ:ALZNAlzamend Neuro Inc
2024/05/1705:30Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:ALZNAlzamend Neuro Inc
2024/05/1421:00Business WireAlzamend Neuro Announces Initial Closing of Private PlacementNASDAQ:ALZNAlzamend Neuro Inc
2024/05/1405:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
2024/05/1106:06Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
2024/05/1105:30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALZNAlzamend Neuro Inc
2024/05/1019:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
2024/05/1005:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
2024/05/1005:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
2024/05/0921:00Business WireAlzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 MillionNASDAQ:ALZNAlzamend Neuro Inc
2024/05/0805:31Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
2024/05/0805:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
2024/05/0721:00Business WireAlzamend Neuro Announces Termination of At-the-Market Equity Offering ProgramNASDAQ:ALZNAlzamend Neuro Inc
2024/03/0806:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
2024/02/0306:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
2024/01/0606:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
2023/12/1606:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALZNAlzamend Neuro Inc
2023/12/1122:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
2023/11/2022:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
2023/11/1706:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
2023/11/1622:00Business WireAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementNASDAQ:ALZNAlzamend Neuro Inc
2023/11/1322:00Business WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
2023/10/3105:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
2023/10/3021:00Business WireAlzamend Neuro Announces Reverse Stock SplitNASDAQ:ALZNAlzamend Neuro Inc
2023/10/2321:00Business WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
2023/10/0221:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
2023/09/3005:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
 검색 관련기사 보기:NASDAQ:ALZN

최근 히스토리

CCOM
US100
US Tech 100
NYSE
MRK
Merck
NASDAQ
NVDA
NVIDIA
CCOM
SILVER
SILVER
NASDAQ
MSFT
Microsoft
AMEX
XLF
Financial Select Sector
NASDAQ
AMZN
Amazon.com
NYSE
VZ
Verizon Communications
CCOM
US30
US 30
NYSE
AXP
American Express
AMEX
XLE
Energy Select Sector SPDR
FX
USDEUR
US Dollar vs Euro
USOTC
DTEGY
Deutsche Telekom (QX)
FX
USDJPY
US Dollar vs Yen
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유